AZD-6793

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameAZD-6793
Drug Alias NameAZD6793AZD-6793
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-1 receptor-associated kinase 1 inhibitorsInterleukin-1 receptor modulatorsInterleukin-1 receptor-associated kinase 4 inhibitors
TargetsInterleukin-1 receptor-associated kinase 1Interleukin-1 receptorInterleukin-1 receptor-associated kinase 4
Therapy Area/IndicationsInflammationDiabetes Mellitus, Type 2Pulmonary Disease, Chronic Obstructive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[24] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstraZeneca AB, R&D GothenburgAstrazeneca PlcAstrazeneca Ab +[4] 
Inactive CompaniesN/A
Active IndicationsInflammationPulmonary Disease, Chronic Obstructive
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A